to two old meds make a new med. We'll see with today's case in point of Elity.

Welcome to the Carlet Psychiatry Podcast, keeping psychiatry honest since 2003.

I'm Chris Agen, the editor-in-chief of the Carlat Psychiatry Report.

And I'm Kelly Newsom, a psychiatric MP and a dedicated reader of every issue.

We're continuing our countdown of the most read articles from 2023, with one that Dr. Aiken

wrote on Ovelity, the fast-acting combo of buproprion and dextromethorfen.

You can read all of the top 15 articles free online through the link in the show notes,

or just Google Top 15 Carlet Psychiatry Articles of 2003.

Dr. Aiken has nothing to disclose.

Well, that's not exactly true.

Pray tell.

While researching this piece, I met with a scientist from Axone Therapeutics for lunch,

and he picked up the bill. I tried to intervene, but my timing was off.

And what did you learn at this lunch?

I was trying to get my hands on the unpublished studies.

Those can be very revealing, although sometimes they aren't published because of flaws

in their methodology rather than flaws in the drug.

Well, in this case, I learned that ovelity was tested in treatment-resistant depression, but that it did not separate

from placebo in that study.

So we start this podcast on a disappointing note, especially as it's treatment-resistant

depression where people are most likely to try a new drug like this.

But I'm going to couch that with a reminder that most meds

...